Galectin Therapeutics (GALT) Tops Q2 EPS by 4c

Galectin Therapeutics (NASDAQ: GALT) reported Q2 EPS of ($0.20), $0.04 better than the analyst estimate of ($0.24).

For earnings history and earnings-related data on Galectin Therapeutics (GALT) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Assurant (AIZ) is Piper Sandler's Weekly Focus Idea
• Credo Technology pops 3.5% as Evercore initiates with monster $325 price target